$MIRM News

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals Announces Results From Cohort 2 Of Pivotal PROGRESS Study Of ATEBRIOZ

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156

Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152

Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184

Mirum tees up Livmarli label expansion on Phase III liver disease study success

Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases

Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease

HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $200

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia - Slideshow

Why Is Mirum Pharmaceuticals Stock Gaining Monday?

Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases